Earnings4536SANTEN PHARMACEUTICAL CO.,LTD.
Santen Pharmaceutical Reports FY26 Revenue of 290 billion, Down 3%
TOKYO, May 12 (Pulse News Wire) – Santen Pharmaceutical Co., Ltd. (4536.T) reported consolidated results for fiscal year 2026 ending March.
Revenue was ¥290 billion (-2.8% YoY). operating profit was ¥55,143 million (-7.1%). net profit attributable to shareholders was ¥37,561 million (+4.8%).
Total assets stood at ¥230 billion with an equity ratio of 54.8%. The company declared an annual dividend of ¥19 per share. The full-year forecast for the current fiscal year is revenue of ¥310 billion (+6.6%).
Financial results — FY2026/3 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥291,624M | -2.8% |
| Operating profit | ¥55,143M | -7.1% |
| Net profit | ¥37,561M | +4.8% |
Next period forecast
Revenue
¥311,000M
+6.6%Op. profit
¥59,000M
+7.0%Net profit
¥39,500M
+5.2%Figures in millions of yen
End of article